TapewireFind a company

person · Reporting owner

Poulton Jeffrey V.

Disclosed activity across 3 companies

Tapewire entity
39782
SEC CIK
0001782962

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132EVP, Chief Financial OfficerMarch 04, 2026March 06, 2026
CervoMed Inc.CRVO · Entity 7338DirectorJune 08, 2026June 10, 2026
Q32 Bio Inc.FIXX · Entity 5594DirectorJune 14, 2023June 15, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect61,805 Ending reported balance After 2026-03-04 transaction · row 8
8 source rows · reconciled sequence

Row 1 · 2026-03-04 · Sale · Disposed 114 · Balance 64,159

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2026-03-04 · Sale · Disposed 109 · Balance 64,050

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2026-03-04 · Sale · Disposed 230 · Balance 63,820

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2026-03-04 · Sale · Disposed 309 · Balance 63,511

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2026-03-04 · Sale · Disposed 374 · Balance 63,137

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2026-03-04 · Sale · Disposed 818 · Balance 62,319

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 7 · 2026-03-04 · Sale · Disposed 291 · Balance 62,028

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 8 · 2026-03-04 · Sale · Disposed 223 · Balance 61,805

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Common StockSEC Table I · non-derivativeIndirectby Managed Account57 Reported balance Holding disclosure · report date 2026-03-04 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 57

F10: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

CervoMed Inc.

Report date June 08, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2036-06-08Direct8,150 Reported balance After 2026-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-08 · Grant · Acquired 8,150 · Balance 8,150

F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Q32 Bio Inc.

Report date June 14, 2023 · Filed June 15, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2033-06-14Direct23,000 Reported balance After 2023-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-14 · Grant · Acquired 23,000 · Balance 23,000

F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 317 $454.84 $144,184.28
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 11

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,342

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 428 $453.77 $194,213.56
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 10

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,659

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 869 $452.69 $393,387.61
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 9

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,087

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 432 $451.86 $195,203.52
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 8

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,956

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 704 $450.81 $317,370.24
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 7

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,388

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 324 $449.79 $145,731.96
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 6

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,092

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 234 $448.77 $105,012.18
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 5

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,416

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 73 $447.92 $32,698.16
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 4

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,650

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 150 $446.53 $66,979.50
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 3

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,723

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 4,644 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 2

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,873

F2 · kind: On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 21:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 3,108 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000117 · edgardoc.xml · nonDerivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,229

F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 19 $455.82 $8,660.58
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 9

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,121

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 392 $454.84 $178,297.28
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 8

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,140

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 886 $454.04 $402,279.44
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 7

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,532

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 536 $452.96 $242,786.56
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 6

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,418

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 168 $451.99 $75,934.32
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 5

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,954

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 63 $450.92 $28,407.96
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 4

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,122

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 147 $449.92 $66,138.24
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 3

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,185

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 63 $447.98 $28,222.74
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 2

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,332

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:27 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 4,644 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000090 · edgardoc.xml · nonDerivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,395

F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.

Read SEC document
June 23, 2025 Filed Jun 25, 2025 21:01 UTC CervoMed Inc. CRVO · Entity 7338 GrantStock Option (Right to Buy) · Derivative 8,100 $0.00 Strike: $6.52 $0.00
Disclosure

SEC source: 0001437749-25-021271 · rdgdoc.xml · derivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,100

Underlying: Common Stock · 8,100 shares

Expires 2035-06-23

F1 · derivative.exercise_date: On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 9,800 $0.00 Strike: $243.53 $0.00
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · derivative · entry 10

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,800

Underlying: Common Stock · 9,800 shares

Expires 2035-03-03

F11 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1 $248.36 $248.36
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 8

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,751

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 7 $247.35 $1,731.45
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 7

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,752

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 77 $246.18 $18,955.86
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 6

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,759

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 189 $245.26 $46,354.14
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 5

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,836

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 258 $244.41 $63,057.78
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 4

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,025

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 382 $243.36 $92,963.52
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 3

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,283

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 350 $242.37 $84,829.50
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 2

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,665

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 15,117 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000031 · edgardoc.xml · nonDerivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,015

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

F2 · balance_after: The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,117, newly awarded RSUs and 32,634 shares of common stock. The Reporting Person also holds 1,908 unvested RSUs that were previously reported in Table II.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 59 $244.11 $14,402.49
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 9

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,898

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 121 $243.23 $29,430.83
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 8

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,957

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 300 $242.44 $72,732.00
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 7

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,078

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 127 $241.51 $30,671.77
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 6

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,378

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 78 $240.32 $18,744.96
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 5

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,505

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 35 $239.18 $8,371.30
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 4

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,583

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 34 $238.33 $8,103.22
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 3

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,618

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 42 $236.51 $9,933.42
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 2

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,652

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 27, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionRestricted Stock Units · Derivative 1,908 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · derivative · entry 11

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,908

Underlying: Common Stock · 1,908 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_price: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.

F12 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

F12 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

Read SEC document
February 27, 2025 Filed Mar 3, 2025 21:31 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 1,908 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000022 · edgardoc.xml · nonDerivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,694

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 20 $264.87 $5,297.40
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 13

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,786

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 17 $263.33 $4,476.61
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 12

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,806

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 37 $261.45 $9,673.65
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 11

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,823

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.42 to $261.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 30 $260.57 $7,817.10
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 10

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,860

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $260.31 to $260.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 17 $259.72 $4,415.24
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 9

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,890

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.21 to $260.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 47 $258.07 $12,129.29
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 8

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,907

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.86 to $258.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 37 $257.51 $9,527.87
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 7

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,954

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.05 to $257.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 78 $256.29 $19,990.62
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 6

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,991

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.01 to $256.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 68 $255.56 $17,378.08
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 5

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,069

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.99 to $255.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 160 $254.35 $40,696.00
Disclosure

SEC source: 0001735276-25-000011 · edgardoc.xml · nonDerivative · entry 4

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,137

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.96 to $254.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.